# Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis

> **NCT07626788** · NA · NOT_YET_RECRUITING · sponsor: **Wasuchon Chaichan** · enrollment: 140 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Pentoxifylline 400 mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07626788
- **Lead sponsor:** Wasuchon Chaichan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2027-03
- **Final completion:** 2028-10
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07626788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07626788, "Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07626788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*